Artelo BiosciencesARTL +5.88%31 EV-to-EBITDA is 0.44 as of Jul. 11, 2026. GuruFocus rates ARTL with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 392 Biotechnology companies, Artelo Biosciences ranks better than 85.2% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Artelo Biosciences's enterprise value is $-5.79 Mil.
Artelo Biosciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-13.06 Mil. Therefore, Artelo Biosciences's EV-to-EBITDA for today is 0.44.
The historical rank and industry rank for Artelo Biosciences's EV-to-EBITDA or its related term are showing as below:
ARTL'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.46
Current: 0.44
During the past 12 years, the highest EV-to-EBITDA of Artelo Biosciences was 0.46. The lowest was 0.00. And the median was 0.00.
ARTL's EV-to-EBITDA is ranked better than 85.2% of 392
companies
in the Biotechnology industry
Industry Median: 12.935
vs ARTL: 0.44
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Artelo Biosciences's PE Ratio (TTM) for today is calculated as:
Artelo Biosciences's share price for today is $1.08.
Artelo Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-38.930.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Artelo Biosciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Artelo Biosciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Artelo Biosciences EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Artelo Biosciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Artelo Biosciences's EV-to-EBITDA falls into.
Artelo Biosciences's current Enterprise Value is $-5.79 Mil.
Artelo Biosciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Artelo Biosciences (ARTL) has a EV-to-EBITDA of 0.44 as of Jul. 11, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Artelo Biosciences. According to the industry distribution chart, Artelo Biosciences ranks #58 out of 392 companies in the Biotechnology industry, placing it in the top 14.8%.
Is Artelo Biosciences' EV-to-EBITDA too high?
Artelo Biosciences' current EV-to-EBITDA is 0.44. The Biotechnology industry median EV-to-EBITDA is 12.94. Artelo Biosciences' value of 0.44 is 96.6% below this industry median. Based on the distribution chart, Artelo Biosciences ranks #58 out of 392 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Artelo Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Artelo Biosciences' EV-to-EBITDA compare to REVB and MTNB?
According to the Biotechnology industry distribution chart, Artelo Biosciences ranks #58 out of 392 companies for EV-to-EBITDA. This places Artelo Biosciences in the top 15% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 12.94. Artelo Biosciences' value of 0.44 is 96.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.94, based on 392 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Artelo Biosciences's current EV-to-EBITDA of 0.44 is 96.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Artelo Biosciences. For the Biotechnology industry, the median EV-to-EBITDA is 12.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Artelo Biosciences's current EV-to-EBITDA is 0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artelo Biosciences stock overvalued right now?
Artelo Biosciences (ARTL) has a current EV-to-EBITDA of 0.44. The current EV-to-EBITDA is 0.44 and 96.6% below the Biotechnology industry median of 12.94. Artelo Biosciences' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Artelo Biosciences (ARTL), the current EV-to-EBITDA is 0.44 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
31GF Score
Get the complete analysis for ARTL
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARTL has been successfully added to your 
